We are live on ! Find out more
GTBP icon

GT Biopharma
GTBP

11 hedge funds and large institutions have $35.3M invested in GT Biopharma in 2024 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

5.87% more ownership

Funds ownership: 50.01% → 55.87% (+5.9%)

0% more funds holding

Funds holding: 11 → 11 (0)

7% less capital invested

Capital invested by funds: $38.1M → $35.3M (-$2.82M)

50% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 4

Holders
11
Holders Change
–
Holders Change %
0%
% of All Funds
0.16%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
2
Reduced
4
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale
Germany
+$422K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$9.25K

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$21.2K
2
UBS Group
UBS Group
Switzerland
-$12.1K
3
TRCT
Tower Research Capital (TRC)
New York
-$1.25K
4
BlackRock
BlackRock
New York
-$119
5
FRA
Front Row Advisors
California
-$3

GTBP Hedge Fund Activity: Q3 2024 in Review

11 of the 6,981 institutional investors tracked by Wall St. Rank reported a position in GT Biopharma (GTBP) for Q3 2024, worth a combined $35.3M — down 7.4% from $38.1M a quarter earlier.

Fund positioning in GTBP was balanced in Q3 2024: 0 funds opened new positions, 0 closed out, 2 added to existing stakes and 4 trimmed.

The largest buyer was DekaBank Deutsche Girozentrale, adding an estimated $422K. The largest seller was Susquehanna International Group, cutting an estimated $21.2K.

  • 11 institutional investors held GT Biopharma (GTBP) as of Q3 2024, unchanged from Q2 2024.
  • Funds reported $35.3M of GT Biopharma stock for Q3 2024, down 7.4% quarter-over-quarter.
  • 0 funds opened new GT Biopharma positions in Q3 2024 and 0 closed out.
  • The largest GT Biopharma buyer in Q3 2024 was DekaBank Deutsche Girozentrale, an estimated $422K added.
  • The largest GT Biopharma seller in Q3 2024 was Susquehanna International Group, an estimated $21.2K sold.

Based on aggregated 13F filings for Q3 2024.